image credit: Pexels

BMS gets FDA approval for Krazati in colorectal cancer

June 24, 2024


The FDA has given accelerated approval to Krazati (adagrasib) as a combination with Eli Lilly’s anti-EGFR-antibody Erbitux (cetuximab) to treat patients with KRAS G12C-mutated, locally advanced, or metastatic CRC who have previously received chemotherapy.

At the moment there are two KRAS inhibitors on the market, Krazati and Amgen’s Lumakras (sotorasib), which are both approved as second-line monotherapies for KRAS G12C-mutated non-small cell lung cancer (NSCLC) and in clinical testing for first-line use.

Read More on Pharmaphorum